论文部分内容阅读
目的:探讨对慢性乙型肝炎利用阿德福韦酯联合苦参素进行治疗所取得的临床效果以及其安全性。方法:选择曾于我院进行治疗的慢性乙型肝炎患者60例,将这些患者随机分为两组,每组各有30例,分别作为观察组与对照组。对观察组中患者利用阿德福韦酯联合苦参素来进行治疗,对照组患者单纯利用阿德福韦酯来进行治疗。完成治疗后比较两组患者的ALT复常率,对两组患者的HbeAg转阴率以及HBV-DNA转阴率进行比较,比较两组患者的肝纤维化组合各项指标变化。结果:在完成治疗之后,对两组患者的临床症状以及各项指标进行检查,均有不同程度改善,比较两组患者的ALT复常率,有显著差异存在;对两组患者的HbeAg转阴率以及HBV-DNA转阴率进行比较,有显著差异存在;比较两组患者的肝纤维化组合各项指标变化,有显著差异存在。结论:对慢性乙型肝炎利用阿德福韦酯联合苦参素能够取得较好临床治疗效果,使患者各种临床症状能够得到明显改善,患者病情得到明显好转,该治疗方法的安全性较高,可将其最为慢性乙型肝炎的一种优秀治疗方法在临床上进行推广。
Objective: To investigate the clinical effect and safety of adefovir dipivoxil combined with oxymatrine in the treatment of chronic hepatitis B patients. Methods: Sixty patients with chronic hepatitis B who had been treated in our hospital were selected. These patients were randomly divided into two groups with 30 cases in each group as the observation group and the control group respectively. Patients in the observation group were treated with adefovir dipivoxil combined with matrine, and patients in the control group were treated with adefovir dipivoxil alone. After completion of treatment, ALT normalization rate was compared between the two groups. HbeAg negative conversion rate and HBV-DNA negative conversion rate were compared between the two groups. The changes of liver fibrosis index in the two groups were compared. Results: After the completion of the treatment, the clinical symptoms and the indexes of the two groups were examined to some extent. Compared with the ALT normalization rate in the two groups, there was a significant difference. For the two groups of patients, the HbeAg negative Rate and HBV-DNA negative rate, there are significant differences exist; comparison of two groups of patients with changes in the indicators of liver fibrosis, there are significant differences exist. Conclusion: The use of adefovir dipivoxil combined with oxymatrine in chronic hepatitis B can achieve better clinical therapeutic effect, which can significantly improve various clinical symptoms of patients, and the patients’ condition has obviously improved. The safety of this treatment is high , Can be an excellent treatment for its most chronic hepatitis B in the clinical promotion.